drugset / Trial / NCT01790035

Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer

NCT01790035 ↗

Phase 1 Terminated 23 enrolled Washington University School of Medicine
RandomizedParallel-groupDouble-blindTreatment

Summary

Phase 3 placebo-controlled trial to determine efficacy of the probiotic LGG for reducing acute treatment related GI toxicity in patients with GI malignancy with phase 1 safety lead-in.

Timeline

Start
2014-08-19
Primary completion
2017-01-12
Completion
2021-12-12

Outcome

Outcome not reported

Stopped (Enrollment): “Low accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject Lactobacillus rhamnosus GG Other / unclassified 1e+10 cells Oral